Scientific Advisory Board

Endocrinology  |  Metabolic Surgery  |  Gastroenterology

GI Dynamics is privileged to have as our scientific advisors a prestigious, multidisciplinary group of leaders dedicated to advancing research for the treatment of type 2 diabetes, obesity and other metabolic disorders.

 

Endocrinology

David E. Cummings, MD

Endocrinologist, Washington, DC, U.S.A

“I’m very excited to join the team at GI Dynamics and help move EndoBarrier forward,” said Cummings. “This novel device has strong potential to recapitulate some of the magic of bariatric/metabolic operations for type 2 diabetes and obesity without the invasiveness of surgery.”

Carel le Roux, MD, PhD

Endocrinologist, Dublin, Ireland

“Type 2 diabetes remains one of the most challenging chronic diseases people struggle with. Novel and scalable treatments that can have a positive impact on people’s lives are urgently needed,” said Le Roux. “EndoBarrier has broken the mold of how we used to think about novel treatments for diabetes.”

Metabolic Surgery

Ricardo Cohen, MD

Bariatric / Metabolic Surgeon, Sao Paulo, Brazil

“GI Dynamics with EndoBarrier has produced an excellent adjuvant tool to achieve diabetes control,” said Dr. Cohen. “I look forward to helping GI Dynamics continue to develop EndoBarrier to provide a safe and effective device in a treatment area that is growing rapidly.”

Jan Willem Greve, MD, PhD

Bariatric / Metabolic Surgeon, Heerlen, Netherlands

“Obesity and its co-morbidities are an immense challenge for modern health care,” said Greve. “Bariatric or metabolic surgery is a proven tool to treat morbidly obese patients with type 2 diabetes. However, the majority of these patients may have a BMI that is too low or have serious contraindications that preclude them from being candidates for such an invasive surgical procedure. As a bariatric / metabolic surgeon, I believe EndoBarrier is a powerful addition to our treatment armamentarium.”

Francesco Rubino, MD

Bariatric / Metabolic Surgeon, London, UK

“The potential impact of EndoBarrier for the treatment of both type 2 diabetes and obesity in less obese patients is truly exciting. I look forward to working with the GI Dynamics SAB to further study EndoBarrier and its many benefits for patients.”

Philip Schauer, MD

Bariatric / Metabolic Surgeon, Cleveland, OH, U.S.A.

“EndoBarrier is bridging the gap in care for patients struggling to control their HbA1c levels with ever-increasing doses of insulin but do not meet the criteria for gastric bypass surgery. I am excited to help advance the tools that will provide a powerful treatment option for this patient population.”

Gastroenterology

Gerald Holtmann, MD

Gastroenterologist, Brisbane, Australia

“With my current research focused on the role of gut microbiome and brain¬–gut interactions, I’m excited to contribute to the GI Dynamics SAB,” said Dr. Holtmann. “Understanding the role of EndoBarrier should produce interesting research that will hopefully help patients.”

Manoel Galvao Neto, MD

Gastroenterologist, Sao Paulo, Brazil

“Since my first-in-human EndoBarrier implant in 2005, I have seen the health benefit it offers to patients in need of an alternative treatment,” said Galvao. “I truly believe EndoBarrier fills the existing type 2 diabetes treatment gap.”

Thomas Rösch, MD

Gastroenterologist, Hamburg, Germany

“The innovation of endoscopic procedures continues to advance treatments in many disease states,” said Dr. Rösch. “By being part of the GI Dynamics Scientific Advisory Board, I will have the opportunity to help understand these innovations and hopefully advance treatment for the many people diagnosed with obesity and type 2 diabetes.”

Christopher C Thompson, MD FACG AGAF FASGE

Gastroenterologist, Boston, MA, U.S.

“EndoBarrier is an exciting and novel technology that fills a rapidly expanding treatment gap in the management of type 2 diabetes and obesity. The GI Dynamics team has pioneered the advancement of our understanding of disease and treatment mechanisms over the past decade, and this device holds tremendous promise,” said Dr. Thompson. “I am thrilled to be joining such an accomplished group of clinicians and look forward to collaborating with them.”